Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

HISTORICAL FACTS: Abbott laboratories | History Defined

Is Abbott Laboratories Stock Underperforming the Dow?

Abbott Laboratories has trailed the Dow Jones Industrial Average over the past year, but analysts remain highly optimistic about the company's long-term growth prospects.

Barchart

3 Ultra-Reliable Dividend Kings Trading at Bargain-Basement Prices

These beaten-down Dividend Kings, trading near their 2026 lows, offer income, rebound potential, and Wall Street-backed upside for patient investors.

Barchart

Abbott Laboratories Stock Is Getting Decimated, But the Smart Money Senses Opportunity

While ABT stock appears poised to reach the year’s halfway mark in ignominy, the options market is quietly signaling a possible recovery.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

3 Dividend Aristocrats Under $100 to Buy and Hold Forever

These three Dividend Aristocrats under $100 offer steady payouts, reasonable payout ratios, and analyst-backed upside potential.

Barchart

Insider Trades: Okta and Abbott See Buys, Micron Insiders Sell

See the recent insider activity surrounding Okta, Micron Technology, and Abbott Laboratories, and what these moves signal to investors.

MarketBeat

Abbott Stock Crash: Rebound Could Be Coming Fast

Abbott Laboratories' stock price sell-off is overextended in mid-April, creating an opportunity that income investors will not want to miss.

MarketBeat

Stocks Edge Higher as Chipmakers Rebound

The S&P 500 Index ($SPX ) (SPY ) today is up +0.21%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.05%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.43%. June E-mini S&P futures (ESM26 ) are up +0.26%, and June E-mini Nasdaq futures...

Barchart

Read news from The Economist, FT, and more,
with one subscription

A Dividend King on Sale: Is Abbott Labs a Healthcare Bargain?

Abbott Laboratories' recent stock price dip contrasts with its strong Medical Devices division, creating a noteworthy opportunity for dividend investors.

MarketBeat

Comparing 2 Healthcare Giants: Which Dividend Aristocrat Will Keep Paying Out for Generations to Come?

Johnson & Johnson offers scale and stability, but Abbott’s cheaper valuation, higher yield, and stronger upside make it the more attractive pick now.

Barchart

Buy the Dip: These 3 Over-$100 Stocks Just Hit New 52-Week Lows

Among the 128 new 52-week lows on the NYSE on Tuesday, there were five with share prices of $100 or higher. Not all of them are worth buying on the dip. We rate three that could be.

Barchart

This Dividend King Is Down 26%. When Will It Bounce Back?

Abbott Laboratories is down 26% from its 52-week high due to a soft quarter. With 54 consecutive years of dividend hikes and guidance calling for mid-single-digit organic sales growth plus 10% EPS expansion, the Dividend King seems discounted, but the question is, can it rebound?

Barchart

3 High Dividend Growth Kings for Generations of Income That Are Still Rated ‘Buy’

These 3 Dividend Kings combine steady businesses, rising dividends, and solid upside potential for long-term income investors.

Barchart

Do Wall Street Analysts Like Abbott Laboratories Stock?

While Abbott Laboratories has underperformed the broader market over the past year, Wall Street analysts maintain a bullish outlook on the stock’s prospects.

Barchart

These Are the 3 Top Oversold S&P 500 Stocks. Should You Buy the Dip?

Abbott, Roper, and Humana are three blue-chip oversold stocks with significant upside potential for shareholders in January 2026.

Barchart

Get all your
news in one place.

100's of premium titles.
One news app.

MarketBeat

Is Abbott’s January Pullback a Good Time to Buy?

Abbott Laboratories' January price pullback is a signal to load up on shares; this Dividend Aristocrat is growing its business and driving cash flow.

Barchart

Stocks Supported by Easing Geopolitical Tensions and Solid US Economic News

The S&P 500 Index ($SPX ) (SPY ) today is up +0.56%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.72%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.59%. March E-mini S&P futures (ESH26 ) are up +0.52%, and March E-mini Nasdaq futures...

MarketBeat

2 Healthcare Names That Could Get a Big Boost From Earnings

Both Abbott Laboratories and Intuitive Surgical report fourth-quarter results in late January—and both companies offer investors multiple reasons to be bullish.

Barchart

What You Need to Know Ahead of Abbott Laboratories' Earnings Release

Abbott Laboratories is expected to release its fiscal fourth-quarter earnings soon, and analysts project a low double-digit profit growth.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

FDA Warns Against Abbott Glucose Monitor Sensors After Reports Of Over 700 Injuries, 7 Deaths

The U.S. Food and Drug Administration (FDA) in December issued a safety alert urging people with diabetes to stop using select glucose sensors made by Abbott Laboratories’ (NYSE:ABT) Diabetes Care, after the company linked the devices to seven deaths and hundreds of serious injuries.

Barchart

Is Abbott Laboratories Stock Underperforming the S&P 500?

Abbott Laboratories has lagged behind the S&P 500 in recent months as well as over the past year, yet analysts remain strongly bullish on the stock’s prospects.

International Business Times UK

Abbott-Exact Sciences Deal Set to Shake Up Diagnostic Market with Cancer-Fighting Acquisition

Rumours fly that Abbott is very close to sealing the deal to acquire cancer treatment champion Exact Sciences.

Barchart

Abbott Laboratories Stock Outlook: Is Wall Street Bullish or Bearish?

Despite underperforming the broader market over the past year, Wall Street analysts remain highly bullish on Abbott Laboratories' long-term outlook.

Barchart

5 Dividend Aristocrats Proving That Reliability Still Pays in 2025

These five companies offer stability in terms of growth and income.

MarketBeat

Abbott Laboratories' October Price Plunge Is a Signal to Buy

Abbott Laboratories is on track to reach new highs, potentially by early 2026, opening the door for a 30% stock price increase in addition to the dividend.

Benzinga

These Analysts Revise Their Forecasts On Abbott Following Q3 Results

Abbott Laboratories (NYSE:ABT) reported muted sales in the third quarter and narrowed fiscal 2025 guidance on Wednesday.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Dow Jones Industrial Average

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.